Press releases
- RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment
- RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88
- RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
- RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
More ▼
Key statistics
On Friday, RemeGen Co Ltd (9995:HKG.HS) closed at 25.70, 71.79% above the 52 week low of 14.96 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.45 |
---|---|
High | 26.40 |
Low | 25.35 |
Bid | 25.70 |
Offer | 25.95 |
Previous close | 25.45 |
Average volume | 1.85m |
---|---|
Shares outstanding | 544.33m |
Free float | 307.55m |
P/E (TTM) | -- |
Market cap | 23.06bn HKD |
EPS (TTM) | -3.03 HKD |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼